ALK-N001 for Injection

DRUG2 trials

Sponsors

Zhejiang Anglikang Pharmaceutical Co., Ltd.

Conditions

Advance Solid TumorsAdvanced Solid Tumors

Phase 1

A Phase Ib/II Study Evaluating Injectable ALK-N001 in Patients With Advanced Solid Tumors

Not yet recruitingNCT07509684

Zhejiang Anglikang Pharmaceutical Co., Ltd.Advanced Solid Tumors

Start: 2026-04-01End: 2029-06-01Target: 190Updated: 2026-04-13

A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors

SuspendedNCT07529535

Zhejiang Anglikang Pharmaceutical Co., Ltd.Advance Solid Tumors

Start: 2025-06-05End: 2026-12-01Updated: 2026-04-17